巴瑞替尼在获得持续疾病控制的类风湿关节炎患者中的剂量递减:一项前瞻性研究结果
在巴瑞替尼4 mg治疗≥15个月且维持CDAI低疾病活动度或缓解的类风湿关节炎患者中,盲法随机继续4 mg或减至2 mg,随访48周。继续4 mg组维持低疾病活动度80%、缓解40%,减量组分别为67%和33%;减量组疾病活动度小幅但统计学显著升高,复发更早更频繁(4 mg组23% vs 2 mg组37%,p=0.001),补救率分别为10%和18%。
要点
- 巴瑞替尼4 mg治疗获得持续低疾病活动度或缓解后,继续4 mg维持疾病控制优于减至2 mg。
- 减至2 mg组48周内复发率37%,高于继续4 mg组的23%(p=0.001),补救率分别为18%和10%。
- 减至2 mg组多数患者仍可维持低疾病活动度或缓解,或恢复4 mg后重获控制。
核心结论
- 在诱导持续低疾病活动度或缓解后,继续巴瑞替尼4 mg维持类风湿关节炎控制的患者比例高于减至2 mg者,但减至2 mg的多数患者仍可维持低疾病活动度或缓解,或恢复4 mg后重获控制。
研究设计与样本
- 完成巴瑞替尼3期研究的患者可进入长期扩展研究,其中接受巴瑞替尼4 mg≥15个月且维持CDAI低疾病活动度或缓解者被盲法随机分配继续4 mg或递减至2 mg,必要时可补救至4 mg,疗效和安全性评估至48周。
主要发现
- 48周内两组维持低疾病活动度比例分别为巴瑞替尼4 mg组80%和2 mg组67%,维持缓解比例分别为4 mg组40%和2 mg组33%。
- 剂量递减导致第12、24和48周疾病活动度出现小幅但统计学显著的升高。
- 48周内剂量递减组复发(失去递减标准)更早且更频繁,巴瑞替尼4 mg组23% vs 2 mg组37%(p=0.001)。
- 补救率巴瑞替尼4 mg组为10%,2 mg组为18%。
- 剂量递减与数值上较低的非严重感染率相关(巴瑞替尼4 mg组30.6 vs 2 mg组24.9),严重不良事件率和导致停药的不良事件率两组相似。
关键数值与推荐
- 维持低疾病活动度:巴瑞替尼4 mg组80% vs 2 mg组67%。
- 维持缓解:巴瑞替尼4 mg组40% vs 2 mg组33%。
- 48周内复发(失去递减标准):巴瑞替尼4 mg组23% vs 2 mg组37%(p=0.001)。
- 补救率:巴瑞替尼4 mg组10% vs 2 mg组18%。
- 非严重感染率:巴瑞替尼4 mg组30.6 vs 2 mg组24.9。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study investigated the effects of dose step-down in patients with rheumatoid arthritis (RA) who achieved sustained disease control with baricitinib 4 mg once a day. METHODS: Patients who completed a baricitinib phase 3 study could enter a long-term extension (LTE). In the LTE, patients who received baricitinib 4 mg for ≥15 months and maintained CDAI low disease activity (LDA) or remission (REM) were blindly randomised to continue 4 mg or taper to 2 mg. Patients could rescue (to 4 mg) if needed. Efficacy and safety were assessed through 48 weeks. RESULTS: Patients in both groups maintained LDA (80% 4 mg; 67% 2 mg) or REM (40% 4 mg; 33% 2 mg) over 48 weeks. However, dose reduction resulted in small, statistically significant increases in disease activity at 12, 24 and 48 weeks. Dose reduction also produced earlier and more frequent relapse (loss of step-down criteria) over 48 weeks compared with 4 mg maintenance (23% 4 mg vs 37% 2 mg, p=0.001). Rescue rates were 10% for baricitinib 4 mg and 18% for baricitinib 2 mg. Dose reduction was associated with a numerically lower rate of non-serious infections (30.6 for baricitinib 4 mg vs 24.9 for 2 mg). Rates of serious adverse events and adverse events leading to discontinuation were similar across groups. CONCLUSIONS: In a large randomised, blinded phase 3 study, maintenance of RA control following induction of sustained LDA/REM with baricitinib 4 mg was greater with continued 4 mg than after taper to 2 mg. Nonetheless, most patients tapered to 2 mg could maintain LDA/REM or recapture with return to 4 mg if needed.
引用
- Takeuchi T, Genovese MC, Haraoui B, et al. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. Ann Rheum Dis. 2018. PMID: 30194275. doi:10.1136/annrheumdis-2018-213271
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。